(Q45396765)

English

Recombinant Marek's disease virus (MDV) lacking the Meq oncogene confers protection against challenge with a very virulent plus strain of MDV.

scientific article published on 13 February 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Recombinant Marek's disease virus (MDV) lacking the Meq oncogene confers protection against challenge with a very virulent plus strain of MDV. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

2

object named as

Blanca Lupiani

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

author name string

Lucy F Lee

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Robert F Silva

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Hsing-Jien Kung

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Sanjay M Reddy

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

language of work or name

0 references

publication date

13 February 2008

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1887-1892

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

The attenuation, with loss of oncogenicity, of the herpes-type virus of Marek's disease (strain HPRS-16) on passage in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Immunization against Marek's disease using a live attenuated virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Protection against Marek's Disease by Vaccination with a Herpesvirus of Turkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Characterisation of two highly oncogenic strains of Marek's disease virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Polyvalent Marek's disease vaccines: safety, efficacy and protective synergism in chickens with maternal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Control of Marek's disease in the Netherlands. II. Field trials on vaccination with an avirulent strain (CVI 988) of Marek's disease virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Control of Marek's disease in the Netherlands. I. Isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Chicken industry strategies for control of tumor virus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Serotype 1 viruses modified by backpassage or insertional mutagenesis: approaching the threshold of vaccine efficacy in Marek's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

The glycoprotein B genes of Marek's disease virus serotypes 2 and 3: identification and expression by recombinant fowlpox viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Protection and synergism by recombinant fowl pox vaccines expressing genes from Marek's disease virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Protection and Synergism by Recombinant Fowl Pox Vaccines Expressing Multiple Genes from Marek's Disease Virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

The efficacy of recombinant fowlpox vaccine protection against Marek's disease: its dependence on chicken line and B haplotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

A DNA vaccine containing an infectious Marek's disease virus genome can confer protection against tumorigenic Marek's disease in chickens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

A virus-encoded telomerase RNA promotes malignant T cell lymphomagenesis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

The RNA subunit of telomerase is encoded by Marek's disease virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Pathogenesis of a Marek's disease virus mutant lacking vIL-8 in resistant and susceptible chickens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Marek's disease virus (MDV) encodes an interleukin-8 homolog (vIL-8): characterization of the vIL-8 protein and a vIL-8 deletion mutant MDV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

A Marek's disease virus vIL-8 deletion mutant has attenuated virulence and confers protection against challenge with a very virulent plus strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Marek's disease virus-encoded vIL-8 gene is involved in early cytolytic infection but dispensable for establishment of latency

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Marek's disease virus-encoded Meq gene is involved in transformation of lymphocytes but is dispensable for replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Interaction of MEQ protein and C-terminal-binding protein is critical for induction of lymphomas by Marek's disease virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Rescue of a pathogenic Marek's disease virus with overlapping cosmid DNAs: use of a pp38 mutant to validate the technology for the study of gene function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Attenuation of Marek's disease virus by deletion of open reading frame RLORF4 but not RLORF5a

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Marek disease virus encodes a basic-leucine zipper gene resembling the fos/jun oncogenes that is highly expressed in lymphoblastoid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Induction of strong protection by vaccination with partially attenuated serotype 1 Marek's disease viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Pathogenicity studies with plaque-purified preparations of Marek's disease virus strain CVI-988.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

A herpesvirus ubiquitin-specific protease is critical for efficient T cell lymphoma formation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.046

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.01.046

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45396765&oldid=1775329577"